Samyang Group’s “Croquis” in the Limelight at the Webinar

- Introduction of facelift thread, croquis, during the webinar at the IMCAS Academy

- Research results and surgical methods for croquis shared by renowned medical specialists of dermatology/plastic surgery

- Broke record of the highest number of pre-registered attendees on the topic of facelift thread in the IMCAS Academy and gained global attention from experts

Samyang Group’s facelift thread brand croquis is breaking new ground in facelift thread along with global medical professionals. Croquis is an aesthetic facelift thread brand of Samyang Holdings Biopharmaceuticals Division.

Samyang Holdings Biopharmaceuticals Division (CEO: Um Tae-ung) announced on the 19th that the safety and efficacy of croquis and facelift procedure was introduced at the IMCAS Academy live webinar. The IMCAS Academy is a platform that provides online courses operated by the IMCAS (International Master Course on Aging Science).

IMCAS is one of the top three global cosmetic societies where prominent figures in the field of dermatology and plastic surgery share the latest trends and medical skills. Up to now, the IMCAS hosted seminars in Paris early on in the year, but due to the COVID-19, a real-time webinar was hosted through the IMCAS Academy this year.

Samyang Holdings Biopharmaceuticals Division introduced its facelift thread brand “croquis” during this webinar and introduced facelift surgery encompassing the theory, research results, and surgical procedures under the topic of “Croquis PDO Thread Master Class” with worldwide medical professionals.

First, Dr. Hema Sundaram, a dermatologist from the US, started the topic with her lecture on the thread theory of cosmetic surgery. Dr. Sundaram compared the anatomical differences between the faces of Asians and Westerners, as well as introducing a method of using croquis for both ethnic groups. Afterwards, Dr. Henry Delmar, a French dermatologist and a clinical researcher of croquis, announced his follow-up research of center-face contour correction to reconfirm the safety and efficacy of croquis.

Lastly, Director Kang Sung-hoon, a dermatologist from Korea, suggested a new paradigm for facelift surgery. Director Kang redefined the concept of “lift” from conventional facelift surgery to “rearrange,” followed by a demonstration of facelift surgery using croquis. In addition, Director Kang newly introduced “vertical facelift” which broke the stereotype of existing facial lifting. Director Kang’s vertical facelift technique was published in Dermatologic Surgery, a SCI-level dermatology journal, in which its scientific basis was recognized as a surgical method that improves the drawbacks of conventional thread lift through customized surgery according to individual facial features.

About 1,600 experts in the medical field pre-registered for the webinar by Samyang Holdings Biopharmaceuticals Division. Among the countless IMCAS webinars carried out in various categories, it recorded the highest number of pre-registered attendees under the topic of facelift thread of cosmetic surgery, thus proving the high interest from experts all around the globe.

An official from Samyang Group said, “We were able to realize the high interest for croquis by global experts through this webinar. We will use this as an opportunity to leap forward as a major brand for cosmetic surgery thread based on various clinical results and by sharing the excellence of croquis through continuous academic marketing.”

Samyang Holdings Biopharmaceuticals Division beat the odds of being a latecomer in the market through data-centered marketing and is earning trust from the global plastic surgery field. Samyang Holdings Biopharmaceuticals Division aims for evidence-based marketing and is making its best effort to obtain various data to prove a correlation between operative effects in each part of the face and the thread’s physical properties, unlike traditional facelift thread brands that only compare and emphasize before and after effects of the operation.